- Home
- JKHY vs RPRX Comparison
JKHY vs RPRX Comparison
Compare JKHY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | RPRX |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 19.5B |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JKHY | RPRX |
|---|---|---|
| Price | $157.67 | $48.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $197.25 | $47.75 |
| AVG Volume (30 Days) | 781.7K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | 1.54% | ★ 1.96% |
| EPS Growth | ★ 19.31 | N/A |
| EPS | ★ 3.70 | 1.78 |
| Revenue | $1,536,603,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $8.07 | $38.30 |
| Revenue Next Year | $6.31 | $4.80 |
| P/E Ratio | $42.69 | ★ $26.94 |
| Revenue Growth | ★ 7.37 | 5.06 |
| 52 Week Low | $144.13 | $29.66 |
| 52 Week High | $193.39 | $47.98 |
Technical Indicators
Market Signals| Indicator | JKHY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 69.54 |
| Support Level | $155.58 | $35.32 |
| Resistance Level | $158.99 | N/A |
| Average True Range (ATR) | 4.02 | 0.88 |
| MACD | -0.64 | 0.12 |
| Stochastic Oscillator | 25.77 | 93.94 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.